Initial experience with non-invasive prenatal testing of cell-free DNA for major chromosomal anomalies in a clinical setting

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 28, Issue 10, 2015, Pages 1196-1201

  Comas, Carmina ^a   Echevarria, Mónica ^a   Rodríguez, M Angeles ^a   Prats, Pilar ^a   Rodríguez, Ignacio ^a   Serra, Bernat ^a  

^a INSTITUT UNIVERSITARI DEXEUS   (Spain)

Author keywords

Cell free DNA; chromosomal anomalies; first trimester screening; non invasive prenatal testing; prenatal diagnosis; trisomy 21

Indexed keywords

CELL FREE DNA; CHORIONIC GONADOTROPIN BETA SUBUNIT; DNA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; CHROMOSOME ABERRATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA DETERMINATION; DOWN SYNDROME; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; GYNECOLOGICAL AND OBSTETRIC DIAGNOSTIC DEVICE; HIGH RISK PREGNANCY; HORMONE BLOOD LEVEL; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LOW RISK POPULATION; MATERNAL AGE; MATERNAL WELFARE; NON INVASIVE PRENATAL TESTING; NUCLEAR MAGNETIC RESONANCE SCANNER; ORAL BIOPSY; PRENATAL DIAGNOSIS; PRENATAL SCREENING; PRIORITY JOURNAL; PROSPECTIVE STUDY; TURNER SYNDROME; CELL FREE SYSTEM; CHROMOSOME DISORDERS; EVALUATION STUDY; GENETICS; PREGNANCY; PROCEDURES; YOUNG ADULT;

ADULT; CELL-FREE SYSTEM; CHROMOSOME DISORDERS; DNA; FEMALE; GESTATIONAL AGE; HUMANS; PREGNANCY; PRENATAL DIAGNOSIS; YOUNG ADULT;

EID: 84940658434     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.3109/14767058.2014.947579     Document Type: Article

References (30)

1. Chiu RW, Akolekar R, Zheng YW, et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validation study. BMJ 2011;342:c7401.
2. Ehrich M, Deciu C, Zweifelhofer T, et al. Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. Am J Obstet Gynecol 2011;204:205.e201-11.
3. Palomaki GE, Kloza EM, Lambert-Messerlian GM, et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med 2011;13:913-20.
4. Sparks AB, Struble CA, Wang ET, et al. Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012;206:319.e1-9.
5. Ashoor G, Syngelaki A, Wagner M, et al. Chromosome-selective sequencing of maternal plasma cell-free DNA for first-trimester detection of trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012; 206:322.e1-5.
6. Norton ME, Brar H, Weiss J, et al. Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012;207:137.e1-8.
7. Bianchi DW, Platt LD, Goldberg JD, et al. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol 2012;119:890-901.
8. Nicolaides KH, Syngelaki A, Ashoor G, et al. Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population. Am J Obstet Gynecol 2012;207:374.e1-6.
9. Malone FD, Canick JA, Ball RH, et al. First-trimester or secondtrimester screening, or both, for Down's syndrome. N Engl J Med 2005;353:2001-11.
10. Kagan KO, Etchegaray A, Zhou Y, Wright D, Nicolaides KH. Prospective validation of first trimester combined screening for trisomy 21. Ultrasound Obstet Gynecol 2009;34:14-18.
11. Nicolaides KH. Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn 2011;31:7-15.
12. Palomaki GE, Deciu C, Kloza EM, et al. DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. Genet Med 2012;14:296-305.
13. Stumm M, Entezami M, Haug K, et al. Diagnostic accuracy of random massively parallel sequencing for non-invasive prenatal detection of common autosomal aneuploidies: a collaborative study in Europe. Prenat Diagn 2014;34:185-91.
14. Lau TK, Chan MK, Lo PS, et al. Clinical utility of noninvasive fetal trisomy (NIFTY) test-early experience. J Matern Fetal Neonatal Med 2012;25:1856-9.
15. Dan S, Wang W, Ren J, et al. Clinical application of massively parallel sequencing-based prenatal noninvasive fetal trisomy test for trisomies 21 and 18 in 11,105 pregnancies with mixed risk factors. Prenat Diagn 2012;32:1225-32.
16. Song Y, Liu C, Qi H, et al. Noninvasive prenatal testing of fetal aneuploidies by massively parallel sequencing in a prospective Chinese population. Prenat Diagn 2013;33:700-6.
17. Bianchi DW, Parker RL, Wentworth J, et al. DAN sequencing versus standard prenatal aneuploidy screening. N Engl J Med 2014; 370:799-808.
18. Verweij EJ, Jacobsson B, van Scheltema PA, et al. European noninvasive trisomy evaluation (EU-NITE) study: a multicenter prospective cohort study for non-invasive fetal trisomy 21 testing. Prenat Diagn 2013;33:996-1001.
19. Gil MM, Quezada MS, Bregant B, et al. Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies. Ultrasound Obstet Gynecol 2013;42:34-40.
20. Fairbrother G, Johnson S, Musci TJ, Song K. Clinical experience of noninvasive prenatal testing with cell-free DNA for fetal trisomies 21, 18, and 13, in a general screening population. Prenat Diagn 2013;33:580-3.
21. Zimmermann B, Hill M, Gemelos G, et al. Noninvasive prenatal aneuploidy testing of chromosomes 13, 18, 21, X, and Y, using targeted sequencing of polymorphic loci. Prenat Diagn 2012;32: 1233-41.
22. Nicolaides KH, Syngelaki A, Gil M, et al. Validation of targeted sequencing of single-nucleotide polymorphisms for non-invasive prenatal detection of aneuploidy of chromosomes 13, 18, 21, X, and Y. Prenat Diagn 2013;33:575-9.
23. Canick JA, Palomaki GE, Kloza EM, et al. The impact of maternal plasma DNA fetal fraction on next generation sequencing tests for common fetal aneuploidies. Prenat Diagn 2013;33:667-74.
24. Wang E, Batey A, Struble C, et al. Gestational age and maternal weight effects on fetal cellfree DNA in maternal plasma. Prenat Diagn 2013;33:662-6.
25. Futch T, Spinosa J, Bhatt S, et al. Initial clinical laboratory experience in noninvasive prenatal testing for fetal aneuploidy from maternal plasma DNA samples. Prenat Diagn 2013;33: 569-74.
26. Song K, Musci TJ, Caughey AB. Clinical utility and cost of noninvasive prenatal testing with cfDNA analysis in high-risk women based on a US population. J Matern Fetal Neonatal Med 2013;26: 1180-5.
27. Garfield SS, Amstrong SO. Clinical and cost consequences of incorporating a novel non-invasive prenatal test into the diagnostic pathway for fetal trisomies. J Manag Care Med 2012; 15:34-41.
28. Manegold-Brauer G, Kang Bellin A, Hahn S, et al. A new era in prenatal care: non-invasive prenatal testing in Switzerland. Swiss Med Wkly 2014;144:w13915:1-5.
29. Ashoor G, Poon L, Syngelaki A, et al. Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks' gestation: effect of maternal and fetal factors. Fetal Diagn Ther 2012;31:237-43.
30. American College of Obstetricians and Gynecologists. Committee Opinion No. 545: noninvasive prenatal testing for fetal aneuploidy. Obstet Gynecol 2012;120:1532-4.